From: Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors
Target | AQUA scores, primary specimens (mean ± SD) | AQUA scores, metastatic specimens (mean ± SD) | t-statistic | p-value |
---|---|---|---|---|
B-Raf | 32.1 ± 8.9 | 31.2 ± 10.2 | −0.417 | 0.678 |
C-Raf | 26.7 ± 2.1 | 28.4 ± 2.5 | 0.519 | 0.605 |
cKit | 23.3 ± 1.3 | 23.4 ± 1.3 | 0.079 | 0.937 |
FGF-R1 | 29.1 ± 1.1 | 29.9 ± 0.9 | 0.579 | 0.564 |
HIF-2α | 58.2 ± 1.9 | 58.2 ± 2.0 | 0.014 | 0.989 |
mTOR | 18.8 ± 1.4 | 22.4 ± 1.8 | 1.637 | 0.106 |
PDGF-Rβ | 24.7 ± 0.9 | 27.9 ± 1.5 | 1.879 | 0.064 |
VEGF-R1 | 22.6 ± 0.9 | 23.9 ± 1.2 | 0.34 | 0.735 |
VEGF-R2 | 36.5 ± 2.4 | 33.5 ± 1.7 | −1.294 | 0.200 |
VEGF-R3 | 45.6 ± 2.0 | 46.5 ± 1.6 | 0.371 | 0.712 |
VEGF | 24.7 ± 1.0 | 26.0 ± 1.1 | 0.907 | 0.367 |
VEGF-B | 11.2 ± 0.6 | 11.8 ± 0.9 | 0.486 | 0.628 |
VEGF-C | 17.0 ± 1.3 | 14.3 ± 1.2 | −1.544 | 0.127 |
VEGF-D | 35.0 ± 1.2 | 36.8 ± 1.3 | 1.018 | 0.312 |
MEK1 | 37.5 ± 2.5 | 50.3 ± 3.1 | 3.183 | 0.002 |
ERK1/2 | 17.0 ± 1.1 | 18.6 ± 1.7 | 0.802 | 0.425 |